Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2016

Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections

(1) , (2, 1) , (1, 3) , (1) , , , (4) , (5) , , , , (6, 2)
1
2
3
4
5
6

Résumé

Teicoplanin is a key drug for the treatment of multiresistant staphylococcal bone and joint infections (BJI), yet can only be administered via a parenteral route. The objective of this study was to evaluate the safety and tolerability of subcutaneous (s.c.) teicoplanin for that indication over 42 days. Thirty patients with Gram-positive cocci BJI were included. Once the target of 25 to 40 mg/liter trough serum concentration was achieved, treatment was switched from an intravenous to an s.c. route. No discontinuation of teicoplanin related to injection site reaction and no severe local adverse event were observed. On multivariate analysis, better tolerability was observed at the beginning of treatment, in patients over 70 years old, and for dosages less than 600 mg. In conclusion, we recommend s.c. administration of teicoplanin when needed.

Dates et versions

hal-03564816 , version 1 (10-02-2022)

Identifiants

Citer

Youssef El Samad, Jean-Philippe Lanoix, Youssef Bennis, Momar Diouf, Carlo Saroufim, et al.. Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections. Antimicrobial Agents and Chemotherapy, 2016, 60 (10), pp.6365-6368. ⟨10.1128/AAC.00351-16⟩. ⟨hal-03564816⟩
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More